Table 6. Complications and treatments of COVID-19 patients.
all (n=1000) | age<60(n=473) | 60-74(n=359) | age≥75(n=168) | |
Complications, No. (%) | ||||
Shock | 81 (8.1%) | 26 (5.5%) | 29 (8.1%) | 26 (15.5%)*# |
Acute cardiac injury | 116 (11.6%) | 19 (4%) | 45 (12.5%)* | 52 (31%)*# |
Acute renal injury | 29 (2.9%) | 6 (1.3%) | 12 (3.3%)* | 11 (6.5%)* |
Acute liver injury | 64 (6.4%) | 36 (7.6%) | 23 (6.4%) | 5 (3%)* |
≥1 complication | 191 (19.1%) | 62 (13.1%) | 68 (18.9%)* | 61 (36.3%)*# |
Only one complication | 125 (12.5%) | 49 (10.4%) | 40 (11.1%) | 36 (21.4%)*# |
≥2 complications | 66 (6.6%) | 13 (2.7%) | 28 (7.8%)* | 25 (14.9%)*# |
Admission to ICU, No. (%) | 63 (6.3%) | 20 (4.2%) | 26 (7.2%) | 17 (10.1%)* |
ICU treatment duration, day, | 7 (3,11) | 7 (4,11) | 10 (5,12) | 4 (2,7)# |
Median (IQR) | ||||
Oxygen therapy, No. (%) | ||||
Nasal catheter oxygen inhalation | 661 (66.1%) | 270 (57.1%) | 261 (72.7%)* | 130 (77.4%)* |
Mask oxygen inhalation | 314 (31.4%) | 120 (25.4%) | 120 (33.4%)* | 74 (44%)*# |
HFBHTI | 91 (9.1%) | 29 (6.1%) | 35 (9.7%) | 27 (16.1%)*# |
Non-invasive mechanical ventilation | 147 (14.7%) | 46 (9.7%) | 57 (15.9%)* | 44 (26.2%)*# |
Invasive mechanical ventilation | 43 (4.3%) | 15 (3.2%) | 18 (5%) | 10 (6%) |
Medical treatment, No. (%) | ||||
Antiviral treatment | 927 (92.7%) | 435 (92%) | 340 (94.7%) | 152 (90.5%) |
Antibiotic treatment | 783 (78.3%) | 362 (76.5%) | 288 (80.2%) | 133 (79.2%) |
Antifungal treatment | 32 (3.2%) | 11 (2.3%) | 15 (4.2%) | 6 (3.6%) |
Glucocorticoids | 500 (50%) | 220 (46.5%) | 197 (54.9%)* | 83 (49.4%) |
Immunoglobulin therapy | 513 (51.3%) | 219 (46.3%) | 200 (55.7%)* | 94 (56%)* |
Special treatment, No. (%) | ||||
CRRT | 15 (1.5%) | 6 (1.3%) | 6 (1.7%) | 3 (1.8%) |
ECMO | 2 (0.2%) | 2 (0.4%) | 0 (0%) | 0 (0%) |
ALSS | 10 (1%) | 6 (1.3%) | 4 (1.1%) | 0 (0%) |
Abbreviation: ALSS: artificial liver support system; CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; IQR: interquartile range. P values indicate differences between male and female patients. * p<0.05 vs. <60 group. # p<0.05vs. 60-74 group.